{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:10:38Z","timestamp":1793916638310,"version":"4.8.0"},"reference-count":141,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["09150162410011"],"award-info":[{"award-number":["09150162410011"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["642991"],"award-info":[{"award-number":["642991"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS136122"],"award-info":[{"award-number":["R01NS136122"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AG084531"],"award-info":[{"award-number":["R01AG084531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AG066519"],"award-info":[{"award-number":["P30AG066519"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AG003991"],"award-info":[{"award-number":["P01AG003991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2011, a workgroup of the Alzheimer's Association Research Roundtable introduced recommendations for detecting and monitoring amyloid\u2010related imaging abnormalities (ARIA) in Alzheimer's disease (AD) clinical trials. Since then, anti\u2010amyloid immunotherapies have received regulatory approval for AD treatment and are beginning to enter clinical practice, underscoring the importance of informing healthcare providers, researchers, and patients about ARIA's implications in real\u2010world settings. In response, the Alzheimer's Association convened a new workgroup to review current knowledge of ARIA, including underlying mechanisms, clinical presentations, associated risk factors, mitigation strategies, radiologic detection methods, patients\u2019 perspectives in treatment decision\u2010making, and outstanding challenges. Here, we outline key insights from this workgroup, highlighting that effective ARIA detection and monitoring in clinical practice requires adherence to robust protocols to mitigate risks and enhance patient safety. Limited availability of clinical and pathologic data on predictors of symptomatic and severe ARIA underscores the importance of continued real\u2010world data collection.<\/jats:p>","DOI":"10.1002\/alz.71361","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:16:01Z","timestamp":1776831361000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Amyloid\u2010related imaging abnormalities (ARIA) in anti\u2010amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup"],"prefix":"10.1002","volume":"22","author":[{"given":"Ellis S.","family":"van Etten","sequence":"first","affiliation":[{"name":"Department of Neurology Leiden University Medical Center  Leiden the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Mahinrad","sequence":"additional","affiliation":[{"name":"Alzheimer's Association  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Grill","sequence":"additional","affiliation":[{"name":"Institute for Memory Impairments and Neurological Disorders University of California Irvine  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School Brown University  Providence Rhode Island USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Atri","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute  Sun City Arizona USA"},{"name":"Banner Alzheimer's Institute  Phoenix Arizona USA"},{"name":"Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petrice M.","family":"Cogswell","sequence":"additional","affiliation":[{"name":"Department of Radiology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammie L. S.","family":"Benzinger","sequence":"additional","affiliation":[{"name":"Mallinckrodt Institute of Radiology Washington University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[{"name":"National Center of Neurology and Psychiatry  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costantino","family":"Iadecola","sequence":"additional","affiliation":[{"name":"Feil Family Brain and Mind Research Institute Weill Cornell Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Lemere","sequence":"additional","affiliation":[{"name":"Department of Neurology Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A. R.","family":"Nicoll","sequence":"additional","affiliation":[{"name":"Clinical Neurosciences Clinical and Experimental Sciences University of Southampton  Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Department of Neurology Massachusetts General Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[{"name":"Alzheimer's Association  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[{"name":"Department of Radiology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Department of Neurology Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2351"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_12_6_1","unstructured":"FDA.FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval 2023.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010converts\u2010novel\u2010alzheimers\u2010disease\u2010treatment\u2010traditional\u2010approval(accessed April 22 2025)"},{"key":"e_1_2_12_7_1","unstructured":"FDA.FDA approves treatment for adults with Alzheimer's disease 2024.https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010treatment\u2010adults\u2010alzheimers\u2010disease(accessed April 22 2025)"},{"key":"e_1_2_12_8_1","unstructured":"Eisai Co. Ltd and Biogen Inc.Eisai Submits New Drug Application for Subcutaneous Formulation of \u201cLEQEMBI\u00ae\u201d for the Treatment of Early Alzheimer's Disease in Japan | Biogen. 2025.https:\/\/investors.biogen.com\/news\u2010releases\/news\u2010release\u2010details\/eisai\u2010submits\u2010new\u2010drug\u2010application\u2010subcutaneous\u2010formulation(accessed February 2 2026)"},{"key":"e_1_2_12_9_1","unstructured":"Eli Lilly and Company.Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease | Eli Lilly and Company. 2025.https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010kisunla\u2010donanemab\u2010receives\u2010marketing\u2010authorization\u20100(accessed February 2 2026)"},{"key":"e_1_2_12_10_1","unstructured":"Leqembi recommended for treatment of early Alzheimer's disease | European Medicines Agency (EMA) 2024.https:\/\/www.ema.europa.eu\/en\/news\/leqembi\u2010recommended\u2010treatment\u2010early\u2010alzheimers\u2010disease(accessed October 2 2025)"},{"key":"e_1_2_12_11_1","unstructured":"Kisunla | European Medicines Agency (EMA) 2025.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisunla(accessed October 14 2025)"},{"key":"e_1_2_12_12_1","unstructured":"Donanemab licensed for early stages of Alzheimer's disease in adult patients who have one or no copies of apolipoprotein E4 gene. GOVUK n.d.https:\/\/www.gov.uk\/government\/news\/donanemab\u2010licensed\u2010for\u2010early\u2010stages\u2010of\u2010alzheimers\u2010disease\u2010in\u2010adult\u2010patients\u2010who\u2010have\u2010one\u2010or\u2010no\u2010copies\u2010of\u2010apolipoprotein\u2010e4\u2010gene(accessed October 14 2025)"},{"key":"e_1_2_12_13_1","unstructured":"Lecanemab licensed for adult patients in the early stages of Alzheimer's disease. GOVUK n.d.https:\/\/www.gov.uk\/government\/news\/lecanemab\u2010licensed\u2010for\u2010adult\u2010patients\u2010in\u2010the\u2010early\u2010stages\u2010of\u2010alzheimers\u2010disease(accessed December 9 2024)"},{"key":"e_1_2_12_14_1","unstructured":"Therapeutic Goods Administration (TGA).TGA approves registration of lecanemab (LEQEMBI) | Therapeutic Goods Administration (TGA) 2025.https:\/\/www.tga.gov.au\/news\/news\/tga\u2010approves\u2010registration\u2010lecanemab\u2010leqembi(accessed October 2 2025)"},{"key":"e_1_2_12_15_1","unstructured":"Therapeutic Goods Administration.KISUNLA donanemab 350 mg\/20 mL concentrated solution for intravenous infusion vial (ARTG ID 420194). Commonwealth of Australia 2025.https:\/\/www.tga.gov.au\/resources\/artg\/420194"},{"key":"e_1_2_12_16_1","volume-title":"Health Canada grants authorization for LEQEMBI\u00ae (lecanemab) for the treatment of early Alzheimer's disease","author":"Biogen Inc","year":"2025"},{"key":"e_1_2_12_17_1","unstructured":"U.S.Department of Veterans Affairs.Lecanemab\u2010irmb (Leqembi) Criteria for Use (rev. 2). VA leqembi 2023.https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/CFU_Lecanemab\u2010irmb_LEQEMBI_CFU_rev2_Aug_2023.pdf(accessed March 25 2025)"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102014\u2010309493"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010160216"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005060"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c67808"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(12)70015\u20107"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010221305"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215148"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010023\u201043933\u20105"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.41"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.34"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8469"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A7586"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12366"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(23)00114\u2010X"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt263"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23857"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52169"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.595181"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000307750.41970.d9"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26761"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000148604.77591.67"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000073623.84147.A8"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(08)61075\u20102"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz142"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm840"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401\u2010010\u20100719\u20105"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq056"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4491"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12642"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102990.2010.01156.x"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn261"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac021"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.10.020"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742\u20102094\u20101\u201024"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.010"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401\u2010014\u20101340\u20109"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750\u20103639.2004.tb00493.x"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000013077"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401\u2010009\u20100498\u2010z"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13512"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(25)00313\u20108"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00099"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(04)00825\u20107"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209582"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10810"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh379"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12946"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.005179"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024\u2010023\u201000660\u20101"},{"key":"e_1_2_12_70_1","doi-asserted-by":"crossref","unstructured":"PloweyED AbettanJ Te ChouPC et\u00a0al.An in vivo model of Amyloid\u2010Related Imaging Abnormalities (ARIA) predicts ARIA incidence of anti\u2010A\u03b2 antibodies seen in clinical trials2026. doi:10.64898\/2026.01.30.702402","DOI":"10.64898\/2026.01.30.702402"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260066.98681.2e"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102013\u2010306485"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593\u2010024\u201001757\u20106"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010018\u201006301\u20102"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22134"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007818"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010024\u201001640\u20103"},{"key":"e_1_2_12_78_1","volume-title":"Latest interim results from the BrainshuttleTM AD study, a phase lb\/lla study of trontinemab in people with alzheimer's disease","author":"Kulic L","year":"2024"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(24)00335\u20101"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207156"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-1007-7"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2006.08.017"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007931"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.embor.7400784"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101004"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094972"},{"key":"e_1_2_12_87_1","article-title":"Modeling mechanisms of amyloid\u2010related imaging abnormalities (aria) in transgenic mice treated with anti\u2010A\u03b2 immunotherapy and imaged with MRI","author":"Bussiere T","year":"2024","journal-title":"ADPDTM 2024 Lisbon Int Conf Alzheimer's Park Dis Relat Neurol Disord"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1078259"},{"key":"e_1_2_12_89_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4337\u201004.2005"},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2377\u201007.2008"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478\u2010015\u20100250\u2010y"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115754"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7522"},{"key":"e_1_2_12_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.093183"},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12987\u2010024\u201000580\u20102"},{"key":"e_1_2_12_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742\u20102094\u20108\u2010115"},{"key":"e_1_2_12_97_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024\u2010023\u201000649\u2010w"},{"key":"e_1_2_12_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024\u2010024\u201000758\u20100"},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201001273\u20108"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010020\u201060319\u20105"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231363"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1008155"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101880"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2261509"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.ads3204"},{"key":"e_1_2_12_106_1","unstructured":"Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC n.d.https:\/\/www.roche.com\/media\/releases\/med\u2010cor\u20102025\u201007\u201028(accessed October 6 2025)"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082852"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz70859_104691"},{"key":"e_1_2_12_109_1","unstructured":"FDA Approves LEQEMBI\u00ae IQLIKTM (lecanemab\u2010irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease 2025.https:\/\/media\u2010us.eisai.com\/2025\u201008\u201029\u2010FDA\u2010Approves\u2010LEQEMBI\u2010R\u2010IQLIK\u2010TM\u2010lecanemab\u2010irmb\u2010Subcutaneous\u2010Injection\u2010for\u2010Maintenance\u2010Dosing\u2010for\u2010the\u2010Treatment\u2010of\u2010Early\u2010Alzheimers\u2010Disease(accessed February 2 2026)"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A4525"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010024\u201001053\u20108"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010019\u20100281\u20102"},{"key":"e_1_2_12_113_1","unstructured":"FDA to recommend additional earlier MRI monitoring for patients with Alzheimer's disease taking Leqembi (lecanemab) 2025.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010recommend\u2010additional\u2010earlier\u2010mri\u2010monitoring\u2010patients\u2010alzheimers\u2010disease\u2010taking\u2010leqembi\u2010lecanemab(accessed November 14 2025)"},{"key":"e_1_2_12_114_1","unstructured":"U.S. Food and Drug Administration.Kisunla (donanemab\u2010azbt) prescribing information. FDA Kisunla label. FDAGov 2024.https:\/\/www.fda.gov\/media\/180803\/download(accessed March 25 2025)"},{"key":"e_1_2_12_115_1","unstructured":"U.S. Food and Drug Administration.Leqembi (lecanemab\u2010irmb) prescribing information. FDA Leqembi label 2023.https:\/\/www.accessdata.fda.gov\/Drugsatfda_docs\/Label\/2023\/761269Orig1s001lbl.pdf(accessed March 25 2025)"},{"key":"e_1_2_12_116_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2021203071"},{"key":"e_1_2_12_117_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1355"},{"key":"e_1_2_12_118_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2018170803"},{"key":"e_1_2_12_119_1","unstructured":"Diana OteroS et\u00a0al.Head\u2010to\u2010Head Comparison of Susceptibility\u2010 Weighted Imaging and T2*\u2010Weighted Gradient\u2010 Recalled Echo MRI Sequences to Detect ARIA\u2010H in the TRAILBLAZER\u2010ALZ 6 Trial of Donanemab. Poster presentation at Alzheimer's Association International Conference 2025"},{"key":"e_1_2_12_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.55800"},{"key":"e_1_2_12_121_1","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000480"},{"key":"e_1_2_12_122_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065"},{"key":"e_1_2_12_123_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.5205"},{"key":"e_1_2_12_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70062"},{"key":"e_1_2_12_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(25)00024\u20109"},{"key":"e_1_2_12_126_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12101"},{"key":"e_1_2_12_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905"},{"key":"e_1_2_12_128_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3937"},{"key":"e_1_2_12_129_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207757"},{"key":"e_1_2_12_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415\u2010025\u201013142\u20109"},{"key":"e_1_2_12_131_1","unstructured":"Lecanemab Two Years Post\u2010Approval: Real\u2010World Case Series and Patient Pathway Learnings From Diverse US Clinical Settings 2025.https:\/\/www.eisaimedicalinformation.com\/neurology\/congress\u2010materials\/aaic\u20102025(accessed October 7 2025)"},{"key":"e_1_2_12_132_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1782"},{"key":"e_1_2_12_133_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209674"},{"key":"e_1_2_12_134_1","unstructured":"Donanemab for the treatment of patients with early symptomatic Alzheimer's Disease: sponsor briefing document.2024.https:\/\/www.fda.gov\/media\/179167\/download"},{"key":"e_1_2_12_135_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.46"},{"key":"e_1_2_12_136_1","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200230"},{"key":"e_1_2_12_137_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207438"},{"key":"e_1_2_12_138_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.22"},{"key":"e_1_2_12_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadm.2018.12.003"},{"key":"e_1_2_12_140_1","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2024.02376"},{"key":"e_1_2_12_141_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.49"},{"key":"e_1_2_12_142_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26511"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71361","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71361","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:58:07Z","timestamp":1783321087000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/alz.71361"],"URL":"https:\/\/doi.org\/10.1002\/alz.71361","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71361"}}